Clinical Characteristics of Incidental Prostate Cancer After Radical Resection of Bladder Cancer
Objective To analyze the clinical characteristics of incidental prostate cancer after radical resection of blad-der cancer.Methods The clinical data of 75 patients with bladder cancer who underwent radical resection were retrospectively analyzed.All patients were not diagnosed as prostate cancer before operation.In addition,the age and stage of bladder cancer were collected,and the differences of clinical data between patients with incidental prostate cancer and those without incidental prostate cancer were statistically compared;Simultaneously statistically analyze the pathological characteristics of patients with incidental prostate cancer;Follow up after surgery and calculate the survival rate of all patients.Results Among the 75 patients,there were 18 cases of incidental prostate cancer,with an incidence rate of 24.00％(18/75);The age of patients with concomitant prostate cancer was higher than that of patients without concomitant prostate cancer,with a statistical difference(P＜0.05);However,there was no statistically significant difference(P＞0.05)in the preoperative International Prostate Symptom Scale(IPSS),Com-prehensive Quality of Life Questionnaire(GQOLI-74),and Prostate Specific Antigen(PSA)between the two groups;The clinical staging of 18 patients with incidental prostate cancer was mostly limited to pT2,with 10 cases(55.56％)of pT1,5 cases(27.78％)of pT2,and 3 cases(16.67％)of pT3;The Gleason score was used to evaluate patients,with 11 cases(61.11％)having a score of＜7,5 cases(27.78％)having a score of=7,and 2 cases(11.11％)having a score of＞7;60 cases were fol-lowed up successfully,the survival rate was 80.00％(60/75),11 cases died of bladder cancer,4 cases died of other diseases.Conclusion Incidental prostate cancer after radical resection of bladder cancer has a high incidence,mostly confined to pT2,and Gleason score is mostly ≤7.Incidental prostate cancer has no significant impact on the overall survival rate of patients with blad-der cancer.
万方数据
维普
